Secondary analysis of GOG-0249 (315 of 601 patients with high-intermediate/high-risk early endometrial cancer): 5-year RFS was 58.7% with p53abn (HR 4.0), 74.4% with dMMR and 83.4% with p53wt; molecular group did not predict benefit of VCB/chemotherapy vs pelvic RT.
Secondary analysisn = 315
Kuroki et al. Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249